MedTrace Logo

Non Invasive Assessment of Heart Failure

NCT04078425 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-01-09

No results posted yet for this study

Summary

1. To Identify the role of aldosterone antagonist in patients of heart failure with preserved ejection fraction.
2. Portray the health profile of heart failure patients admitted in internal medicine department either heart failure with reduced ejection fraction or heart failure with preserved ejection fraction.
3. To compare between patients of right and left sided heart failure by biomarkers and parameters of echocardiographgy
4. Vitamin D and its relation to cardiovascular disease and heart failure.

Conditions

Interventions

DRUG

Aldosterone Antagonists

aldosterone antagonist will be applied to patients of heart failure with preserved ejection fraction, level of the drug will be sampled before administration of the drug and follow up will be sampled after one month

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-01
Primary Completion
2022-03-01
Completion
2022-05-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04078425 on ClinicalTrials.gov